A Trial Comparing the Efficacy and Safety of Insulin Degludec and Insulin Glargine 300 Units/mL in Subjects With Type 2 Diabetes Mellitus Inadequately Treated With Basal Insulin With or Without Oral Antidiabetic Drugs
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1609 participants.
Also called NCT03078478
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,609 participants
- Sponsor
- Registry
-
NCT03078478 -
2016-002801-20
-
- Main results
- Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial
- Other papers using this trial's data
- Cost-Effectiveness of Insulin Degludec Versus Insulin Glargine U300 in the Netherlands: Evidence From a Randomised Controlled Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Canada, Denmark, Estonia, Germany, Greece, Hungary, Norway, Poland, Puerto Rico, Romania, Serbia
- Registry status
- Completed
Technical summary
Registry record NCT03078478. Randomized; no masking; primary purpose treatment. Start 2017-03-13 (actual); primary completion 2019-02-13 (actual). Results posted on 2020-03-12.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Trial Comparing the Efficacy and Safety of Insulin Degludec and Insulin Glargine 300 Units/mL in Subjects With Type 2 Diabetes Mellitus Inadequately Treated With Basal Insulin With or Without Oral Antidiabetic Drugs
- Acronym
- CONCLUDE
- Condition
- Diabetes
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Insulin degludec
- Intervention (Drug)
- Insulin glargine
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct03078478- Content hash
ac59717c52c460e29e813f3022512d1094c56123647349661fa89adba0fe3e97